non responder to semaglutide Why weight‑loss drugs don't work for some people When Weight-Loss Drugs Don't Work

Diabetic ketoacidosis (DKA) risk is a serious concern, particularly for patients using insulin or SGLT2 inhibitors with very-low-carbohydrate diets

On September 22, 2023, the FDA added a warning stating that semaglutide, the drug in Ozempic, has been reported to cause gastrointestinal disorders and bowel injuries

259 These results indicate that p53 activation is a critical event in NDDs

(2021b) and was recently further extended to 36 mycotoxins and bio-measures (Kuhn et al

(ref 16), Nelson and De Ligny (ref 19) and Korenman and Arefeva (ref 31,34) are markedly higher, sometimes by an order of magnitude, than other results and are therefore rejected

Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions